ISSN (Print):
ISSN (Online):
Download PDF Flyer

Current Pharmacogenomics and Personalized Medicine

(Formerly as Current Pharmacogenomics) Limited Time Complementary OA Offer Get Free Open Access by submitting your article by or before
December 31st, 2024

Indexed in: Scopus, Cabell's Directory/Journalytics... View all

Volume 21 , Issues 3, 2024

Back Journal Home

Institutional Members
Topic(s) Covered

4 Topic(s)


Aims & Scope

Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary, peer-reviewed, biomedical journal that reports new findings and cutting-edge concepts in all areas of pharmacology. Special consideration is given to articles on pharmacogenomics and personalized medicine. CPPM is an accelerator for global personalized medicine and pharmacogenomics, as well as preclinical and clinical pharmacology. Importantly, the journal provides a multi-disciplinary, integrated platform from cell to society to address diagnostics and responsible pharmacogenomics applications in developing countries and the entire range of translational science from bench-to-bedside in various therapeutic areas such as oncology, cardiovascular, neuropharmacology, endocrine diseases, amongst others.

CPPM cooperates with the Ibero-American Network of Pharmacogenetics and the Pacific Rim Association for Clinical Pharmacogenetics and welcomes peer reviewed contributions from authors in any global region.

The journal's scope is defined by four inter-connected aims. First, we are interested in genomics/postgenomics biotechnologies and diagnostics that enable global personalized medicine science (including and beyond pharmacogenomics), as long as they explain person-to-person and population differences in disease susceptibility or response to a health intervention, and can be substantiated. Second, we approach personalized medicine as ‘personalized health interventions’ focusing primarily on drug therapy, but also other interventions such as nutrition, vaccines, surgical devices, emerging cell-based therapies that collectively contribute to healthcare. Third, we strive to integrate molecular and clinical investigation with public policy, global health diplomacy and social studies of biotechnology, that collectively shape postgenomics future(s) and innovation trajectories in life sciences. Fourth, we are interested in all aspects of translational pharmacology from preclinical to clinical applications in any therapeutic area that will advance the practice of medicine for the benefit of patients worldwide including non-communicable diseases as well as infectious diseases in the post- COVID world.

Priority will be given to expert reviews/ mini-reviews and research articles that include original ideas and findings related to the scope and mandate of the journal. Unsolicited submissions are welcomed.

Special Offers

30% discount on the single-issue cost to authors on the purchase of issue(s) in which their article is published.
Multiple issue copies at discounted rates.

COPE Compliant
Archived in

"Current Pharmacogenomics and Personalized Medicine provides access to the most recent progress and opinion in this rapidly developing field and is an indispensable source of information for scientists and clinicians who want to keep in touch with the expanding interdisciplinary advancements."

Brian Tomlinson
Professor of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR.

© 2024 Bentham Science Publishers | Privacy Policy